Pregnancy can affect the characteristics of rilpivirine pharmacokinetics: absorption, distribution, metabolism and excretion. This study evaluated antiretroviral pharmacokinetics in pregnant women with HIV, including a cohort receiving rilpivirine as part of their combination antiretrovirals for clinical care. Findings suggest rilpivirine exposure is highly variable as well as lower during pregnancy, compared with the postpartum stage.
Pharmacokinetics of rilpivirine in HIV-infected pregnant women
Written By
Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M, IMPAACT P1026s protocol team
